The additional risk of endometrial cancer associated with unopposed estrogen use in women with other risk factors

Epidemiology

Volumn 10, Issue 6, 1999, Pages 733-738

  Shields, Tammy S ^a   Weiss, Noel S ^a,b,c   Voigt, Lynda F ^a,b   Beresford, Shirley A A ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Conjugated estrogens; Endometrial cancer; Estrogens; Hypertension; Obesity; Oral contraceptives; Parity; Smoking

Indexed keywords

ESTROGEN; ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ARTICLE; BODY MASS; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DATA ANALYSIS; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; POPULATION RESEARCH; PRIORITY JOURNAL; SMOKING;

EID: 0032741712     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001648-199911000-00014     Document Type: Article

References (17)

1. Mishell DR. Estrogen replacement therapy: an overview. Am J Obstet Gynecol 1989;161:1825-1827.
2. Wysowski DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol 1995; 85:6-10.
3. Beresford SAA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458-461.
4. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, Van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274-277.
5. Berman RS, Epstein RS, Lydick E. Risk factors associated with women's compliance with estrogen replacement therapy. J Women's Health 1997;6: 219-226.
6. Green PK, Weiss NS, McKnight B, Voigt LF, Beresford SAA. Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States). Cancer Causes Control 1996;7:575-580.
7. Cole P, MacMahon B. Attributable risk percent in case-control studies. Br J Prev Soc Med 1971;25:242-244.
8. Hoogerland DL, Buchler DA, Crowley JJ, Carr AB. Estrogen use risk of endometrial carcinoma. Gynecol Oncol 1978;6:451-458.
9. Jelovsek FR, Hammond CB, Woodard BH, Draffin R, Lee KL, Creasman WT, Parker RT. Risk of exogenous estrogen therapy and endometrial cancer. Am J Obstet Gynecol 1980;137:85-91.
10. Levi F, La Vecchia C, Gulie C, Franceschi S, Negri E. Oestrogen replacement treatment and the risk of endometrial cancer: an assessment of the role of covariates. Eur J Cancer 1993;29A:1445-1449.
11. Rubin GL, Peterson HB, Lee NC, Macs EF, Wingo PA, Becker S. Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol 1990;162:148-154.
12. Weiss NS, Farewell VT, Szekely DR, English DR, Kiviat N. Oestrogens and endometrial cancer: effect of other risk factors on the association. Maturitas 1980;2:185-190.
13. Brinton LA, Hoover RN, and the Endometrial Cancer Collaborative Group. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. Obstet Gynecol 1993;81:265-271.
14. Hulka BS, Fowler WC, Kaufman DG, Grimson RC, Greenberg BG, Hague CJR, Berger GS, Pulliam CC. Estrogen and endometrial cancer: cases and two control groups from North Carolina. Am J Obstet Gynecol 1980;137: 92-101.
15. Ewertz M, Schou G, Boice JD. The joint effect of risk factors on endometrial cancer. Eur J Cancer Clin Oncol 1988;24:189-194.
16. Kelsey JL, LiVolsi VA, Holford TR, Fischer DB, Mosrow ED, Schwartz PE, O'Connor T, White C. A case-control study of cancer of the endometrium. Am J Epidemiol 1982;116:333-342.
17. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Mcd 1975;293: 1164-1167.